Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 12% revenue increase and 23% EBITDA growth. The company maintains its guidance, indicating confidence in future growth. The dividend declaration and plans for biosimilar launches further support a positive outlook. While gross margins slightly declined, the overall financial health remains robust. The Q&A section addresses concerns effectively, reinforcing management's confidence. Given the positive financial metrics, strategic plans, and shareholder returns, the stock price is likely to see a positive movement in the short term.
Key Financial Performance
Total Revenues (2025) $180.5 million, representing a 12% year-over-year increase. The growth was attributed to increased sales of VARIZIG and KEDRAB in the U.S. market, KAMRAB and GLASSIA in ex-U.S. markets, and an overall increase in sales in the distribution segment through the launch of biosimilars and other products.
Adjusted EBITDA (2025) $42 million, up 23% year-over-year. This increase reflects the company's ability to execute its strategy and generate significant profitable growth through its diverse commercial product portfolio.
Cash from Operating Activities (2025) $25.5 million, contributing to a strong cash position of $75.5 million at year-end 2025. This demonstrates the company's ability to convert profitability into operational cash flow.
Net Income (2025) $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024. The increase was driven by revenue growth and successful marketing activities.
Gross Profit and Gross Margins (2025) Gross profit was $76.4 million, up from $70 million in 2024. Gross margins were 42%, slightly down from 43% in 2024 due to product and market sales mix.
Sales of KEDRAB (2025) Approximately $54 million, exceeding the contract minimum commitment. This reflects strong performance in the U.S. market.
GLASSIA Revenue Contribution (2025) $35 million, derived from growing product sales in ex-U.S. markets and royalty income from Takeda's sales in the U.S. and Canada.
CYTOGAM Revenues (2025) Declined due to increased usage of antivirals like letermovir and maribavir, which benefited from improved market access coverage.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KEDRAB: Lead product with sales increasing to $54 million in 2025, surpassing contract minimums. Firm commitment of $90 million for 2026-2027. Current supply agreement runs through 2031. Significant market share in the U.S. and growing sales internationally.
CYTOGAM: Revenues declined in 2025 due to increased usage of antivirals. Initiated a post-market research program to demonstrate product advantages. SHIELD study launched to explore benefits in high-risk kidney transplant recipients.
Biosimilars: Two additional biosimilars to be launched in Israel in 2026, with several others in the pipeline. Expected annual sales of $15-$20 million within 4-5 years.
MENA region expansion: Commenced distribution activity in the MENA region with initial agreements signed.
Canadian market: Secured a $10-$14 million extension of an existing tender for product supply to Canadian Blood Services for 2026-2028.
Plasma collection centers: Ramping up plasma collection in Houston and San Antonio centers. Houston site FDA-approved; San Antonio site expected approval in H1 2026. Each center expected to generate $8-$10 million annually at full capacity.
Financial performance: 2025 revenues reached $180.5 million, a 12% increase YoY. Adjusted EBITDA grew 23% to $42 million. Net income increased 40% to $20.2 million.
M&A and business development: Actively pursuing in-licensing, collaborations, and M&A transactions to enrich product portfolio and generate synergies with existing operations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Middle East situation and Israeli airspace closure: The evolving situation in the Middle East and the temporary closure of Israeli airspace could impact exports from Israel, although cargo flights have gradually resumed. This poses a potential risk to product supply continuity.
Decline in CYTOGAM revenues: Revenues from CYTOGAM declined in 2025 due to increased usage of antivirals like letermovir and maribavir, which have improved market access coverage. This trend could continue to impact the product's market share and revenue.
Gross margin decline: The gross margin decreased from 43% in 2024 to 42% in 2025, attributed to changes in product and market sales mix. This could affect overall profitability if the trend persists.
Regulatory approval for plasma collection centers: The San Antonio plasma collection center is awaiting FDA approval, expected in the first half of 2026. Any delays in this approval could impact the planned revenue generation and operational capacity.
Increased operating expenses: Operating expenses rose slightly in 2025 due to increased G&A costs required to support expanded commercial operations. This could pressure profitability if not managed effectively.
Dependence on key products and contracts: The company relies heavily on key products like KEDRAB and contracts such as the $90 million commitment from Kedrion through 2027. Any disruption in these agreements could significantly impact revenues.
CYTOGAM clinical data gap: The lack of recent clinical data for CYTOGAM has necessitated a new research program to demonstrate its benefits. Delays or inconclusive results from this program could hinder efforts to regain market share.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Kamada projects total revenues of $200 million to $205 million for 2026, representing a 13% growth compared to 2025 results.
Adjusted EBITDA Guidance for 2026: The company expects adjusted EBITDA to range between $50 million and $53 million, reflecting a 23% growth compared to 2025.
Organic Growth Focus: The 2026 guidance is based solely on organic growth, with no reliance on acquisitions or external factors.
Commercial Product Portfolio Expansion: Kamada plans to continue investing in the commercialization and lifecycle management of its six FDA-approved specialty plasma-derived products to support organic growth in the U.S. and international markets.
Biosimilar Product Launches: The company anticipates launching two additional biosimilar products in Israel in the coming months, with a goal of achieving annual biosimilar sales of $15 million to $20 million within the next 4 to 5 years.
MENA Region Expansion: Kamada has commenced distribution activity expansion to the MENA region, with initial agreements already signed.
Plasma Collection Centers: The company is ramping up plasma collection at its Houston and San Antonio centers, with the San Antonio site expected to receive FDA approval in the first half of 2026. Each center is projected to generate $8 million to $10 million in annual revenues at full capacity.
Business Development and M&A: Kamada is pursuing new in-licensing, collaboration, and M&A opportunities to enrich its product portfolio and generate synergies with its existing operations.
CYTOGAM Post-Market Research Program: The company is conducting a comprehensive post-market research program for CYTOGAM, including the SHIELD study, to demonstrate the product's benefits in managing CMV disease and support increased utilization.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Declaration: The Board and Kamada management declared a dividend of $0.25 per share, totaling approximately $14.4 million, payable on April 6 to shareholders of record as of March 23.
Dividend Policy: The dividend payment aligns with the company's policy to distribute an annual dividend of at least 50% of its annual net income, subject to board discretion and compliance with Israeli Companies law.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is there any change in the protocol for CMV or improvement in the efficacy of antivirals that would change the opportunity for CYTOGAM?
A:There is no change in the protocol for CMV management. Increased access to antivirals, possibly due to insurers now covering them, may have affected CYTOGAM usage. However, the company believes in the need for CYTOGAM as additional protection for high-risk organ transplant recipients. Ongoing clinical work, including the SHIELD study on kidney transplantation, could significantly increase CYTOGAM usage.
Q:Does the dividend payment indicate any change in potential M&A or business development opportunities?
A:No, the dividend payment reinforces confidence in business prospects. The company has sufficient funds for commercial growth, M&A transactions, and dividend payments. They are optimistic about securing an M&A transaction in 2026, which would accelerate growth.
Q:When can we expect gross margin benefits from proprietary plasma collection for specialty plasma?
A:Gross margin benefits from specialty plasma collection are expected to start in 2027 and beyond. Beaumont and Houston centers are FDA-approved, and San Antonio is expected to be approved in H1 2026. Normal source plasma sales will begin in the second half of 2026.
Q:How quickly are the plasma collection centers ramping up, and when will they reach full production?
A:The centers are currently ramped up to 30%-40% and are expected to reach full production by the end of 2027. During this period, normal-source plasma will be sold to external parties, and specialty plasma will be used internally.
Q:When will the two new biosimilars be introduced in 2026, and how will sales ramp up?
A:The two new biosimilars are expected to launch around mid-2026, likely by the end of Q2. Sales will be based on market demand with minimal initial stocking orders.
Q:Is the projected double-digit growth for 2026 primarily from new geographies or the U.S.?
A:The double-digit growth is expected across the entire portfolio and geographies, including the U.S.
Q:Will the $14 million dividend be paid out in one quarter or spread out over the year?
A:The entire $14 million dividend will be paid out in the second quarter of 2026.
Q:What are the performance and future prospects of VARIZIG?
A:VARIZIG performed well in 2025, with significant sales growth due to declining vaccination rates, increased chickenpox outbreaks, and marketing efforts. The trend is expected to continue in 2026, supported by a significant WHO tender for the Latin American region.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the dividend payment timing initially due to technical difficulties, but later clarified it would be paid in the second quarter of 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors filing
Amir investor
CEO Amir
CMV SHIELD
CYTOGAM revenue
Canada immunoglobulin
Center expert
Clinical Director
Companies law
Dr
Kedrion
MENA region
Medical
SHIELD study
agreement addition
collection center
commitment
disease CMV
dividend payment
donor
ex market
expansion distribution
investigator
kidney
operation product
product portfolio
site FDA
situation
specialty plasma
strength
supply
transplant recipient
KMDA Transcript
Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents mixed signals: while there's a positive revenue growth outlook for 2026 and dividend declaration, current financials show a gross margin decline and economic uncertainties. The Q&A session didn't reveal any major concerns, but competitive pressures and regulatory delays pose risks. Without a market cap, assuming moderate impact, the overall sentiment remains neutral, balancing positive long-term guidance against short-term challenges.
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call reveals strong financial performance with a 12% revenue increase and 23% EBITDA growth. The company maintains its guidance, indicating confidence in future growth. The dividend declaration and plans for biosimilar launches further support a positive outlook. While gross margins slightly declined, the overall financial health remains robust. The Q&A section addresses concerns effectively, reinforcing management's confidence. Given the positive financial metrics, strategic plans, and shareholder returns, the stock price is likely to see a positive movement in the short term.
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call reflects strong financial metrics, with revenue and net income growth, disciplined expense management, and a solid cash position. The company's strategic initiatives, including biosimilar launches and plasma collection expansion, are promising. While some analyst concerns about competitive landscape and vague responses on funding were noted, the overall sentiment remains positive. The reiteration of 2025 guidance and a robust product portfolio further support a positive outlook. Given the lack of market cap data, a moderate positive reaction is expected, likely resulting in a 2% to 8% stock price increase.
KMDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
